Skip to main content

Anil Singhal, Edward Tenthoff, Muzammil Mansuri

Premium

Anil Singhal has become chief drug development officer of Martinsried, Germany-based Xerion Pharmaceuticals. He will be based in the company’s Cambridge, Mass., office. Previously, he was vice president at Light Sciences and Pacific Pharmaceuticals, where he led oncology programs through preclinical and clinical stages of development.

 

Edward Tenthoff has joined U.S. Bancorp Piper Jaffray as a senior research analyst on the genomics sector. Tentoff comes to Piper Jaffray from Think Equity Partners, where he also covered genomics and biotechnology companies. Prior to this, Tenthoff covered biotechnology as a senior research analyst at the now-defunct firm Robertson Stephens.

 

Muzammil Mansuri, executive-in-residence at Flagship Ventures, has been appointed to the scientific advisory board of Achillion Pharmaceuticals. Mansuri is currently chairman of Beyond Genomics, and a director and executive chairman of Adaptive Therapeutics. He has previously served as executive vice president and chief operating officer at GPC Biotech. Between 1994 and 2000, Mansuri also held executive positions at Mitotix. Prior to this time, he worked at Bristol-Myers Squibb.

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.